C12N 2740/14011
Deltaretrovirus
Official title: Deltaretrovirus, e.g. bovine leukeamia virus
C12N2740/14011 (Deltaretrovirus) appears on 155 US grants and 106 published applications in this corpus.
Search patents in C12N- Granted patents
- 155
- Published applications
- 106
- Assignees
- 137
- Inventors
- 382
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 5 | 0 |
| 1989 | 5 | 0 |
| 1990 | 3 | 0 |
| 1991 | 7 | 0 |
| 1992 | 0 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 5 | 0 |
| 1996 | 5 | 0 |
| 1997 | 11 | 0 |
| 1998 | 10 | 0 |
| 1999 | 10 | 0 |
| 2000 | 12 | 0 |
| 2001 | 10 | 1 |
| 2002 | 4 | 4 |
| 2003 | 5 | 4 |
| 2004 | 2 | 9 |
| 2005 | 2 | 4 |
| 2006 | 4 | 7 |
| 2007 | 4 | 2 |
| 2008 | 0 | 11 |
| 2009 | 1 | 2 |
| 2010 | 4 | 4 |
| 2011 | 2 | 6 |
| 2012 | 0 | 1 |
| 2013 | 2 | 0 |
| 2014 | 2 | 4 |
| 2015 | 2 | 4 |
| 2016 | 2 | 2 |
| 2017 | 2 | 3 |
| 2018 | 2 | 4 |
| 2019 | 1 | 2 |
| 2020 | 1 | 6 |
| 2021 | 3 | 5 |
| 2022 | 2 | 5 |
| 2023 | 2 | 5 |
| 2024 | 5 | 4 |
| 2025 | 3 | 6 |
| 2026 | 2 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/14022New viral proteins or individual genes, new structural or functional aspects ofIndexing code125
- C12N 2740/14034Use of virus or viral component as vaccineIndexing code21
- C12N 2740/14041Use of virus, viral particle or viral elements as a vectorIndexing code15
- C12N 2740/14021Viruses as suchIndexing code9
- C12N 2740/14051Methods of production or purification of viral materialIndexing code9
- C12N 2740/14023Virus like particles [vlp]Indexing code5
- C12N 2740/14061Methods of inactivation or attenuationIndexing code5
- C12N 2740/14071Demonstrated in vivo effectIndexing code4
All 12 subgroupsShow fewer
Recent patents
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- Promoter having high activity in activated T-cell5 May 2026US 12,618,066 B2Shanghai Cell Therapy Group Co., Ltd.
- VLP-based monovalent ebola vaccines and methods of making and using same30 Sep 2025US 12,427,190 B2Children's Hospital Medical Center
- Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus20 May 2025US 12,303,560 B2Medigen, Inc.
- VLP-based bivalent Ebola vaccines and methods of making and using same22 Apr 2025US 12,280,100 B2Children's Hospital Medical Center
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Htlv-1 nucleic acid lipid particle vaccine18 Dec 2025US 2025/0381264 A2Daiichi Sankyo Company, Limited
- Human t-cell lymphotropic virus type 1 targeting proteins and methods of use13 Nov 2025US 2025/0346636 A1City of Hope
- Replicant / stav for disease treatment and methods of use30 Oct 2025US 2025/0332233 A1
- Non-replicating bovine infectious lymphoma virus (blv) and cells for producing same21 Aug 2025US 2025/0263740 A1The University of Tokyo
Most cited
By later US patents
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998
- Process for preparing virus disease live vaccines107US 4,071,618 AThe Research Foundation for Microbial Diseases of Osaka University · 1978
- Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses70US 6,268,411 B1The Johns Hopkins University · 2001
- Trans-acting transcriptional factors53US 4,738,922 ADana-Farber Cancer Institute, Inc. · 1988
- Stable TatIII cell lines, TatIII gene products, and assay methods41US 4,981,790 ADana-Farber Cancer Institute, Inc. · 1991